Last reviewed · How we verify
Induction without Brentuximab Vedotin
This drug induces a response in lymphoma patients without Brentuximab Vedotin.
This drug induces a response in lymphoma patients without Brentuximab Vedotin. Used for Lymphoma.
At a glance
| Generic name | Induction without Brentuximab Vedotin |
|---|---|
| Also known as | ESHAP treatment as salvage therapy |
| Sponsor | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
The exact mechanism of action is not well understood, but it is believed to work by targeting the underlying biology of lymphoma cells. Further research is needed to fully elucidate its mechanism.
Approved indications
- Lymphoma
Common side effects
- Unknown
Key clinical trials
- Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma (PHASE2)
- BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: